U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

                                   Form 10QSB

                   Quarterly Report Under Section 13 or 15 (d)
                     of the Securities Exchange Act of 1934

                For the Quarterly Period Ended September 30, 2005

                           Commission File No. 0-12968

                        INMEDICA DEVELOPMENT CORPORATION
                        --------------------------------
        (Exact name of small business issuer as specified in its charter)



                     Utah                               87-0397815
             -----------------------------             ------------
            (State or other jurisdiction of        (I.R.S. Employer
             incorporation of organization)       Identification Number)

                         825 North 300 West, Suite N132
                           Salt Lake City, Utah 84103
                           --------------------------
                    (Address of principal executive offices)

                         Registrant's telephone number:
                                 (801) 521-9300
                         ------------------------------

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act of 1934 during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days: Yes [X] No[ ]
The number of shares outstanding of the registrant's only class of common stock,
par value $.001 per share, as of October 11, 2005 was 18,129,493 shares.







                                       1
<PAGE>

PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEET


                              ASSETS
                              ------
                                              As of
                                          September 30,
                                              2005
                                          (Unaudited)
                                           -----------

        CURRENT ASSETS:
           Cash & cash equivalents          $   51,193
           Notes receivable current
             net of unamortized
             discount of $1,169                 88,831
           Prepaid expenses and other              200

                                            ----------
                Total current assets           140,224


        EQUIPMENT AND FURNITURE,
          at cost, less accumulated
          depreciation of $253,609                 265

                                            ----------


                Total assets                $  140,489
                                            ==========




















            See notes to consolidated financial statements



                                       2
<PAGE>

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                     CONSOLIDATED BALANCE SHEET (Continued)

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      -------------------------------------
                                                          As of
                                                      September 30,
                                                           2005
                                                          ------
                                                       (Unaudited)

        CURRENT LIABILITIES:
           Related party consulting fees payable       $    24,000
           Accrued expenses                                  3,412
           Note payable                                    118,830
           Accrued interest                                    264
           Accounts payable                                  3,996
           Preferred stock dividend payable                 32,154
                                                      ------------

                Total current liabilities                  182,656
                                                       -----------

            MINORITY INTEREST                              (18,376)
                                                       -----------

        STOCKHOLDERS' EQUITY:
           Preferred stock, 10,000,000
            shares authorized; Series A
            preferred stock, cumulative and
            convertible, $4.50 par value,
            1,000,000 shares designated,
            21,016 shares issued and
            outstanding                                     94,573
           Common stock, $.001 par value;
            40,000,000 shares authorized,
            18,129,493 issued and outstanding               18,129
           Additional paid-in capital                    8,236,763
           Accumulated deficit                          (8,373,256)
                                                        ----------

                Total stockholders deficit                 (23,791)
                                                        ----------
                Total liabilities and
                 stockholders' deficit                  $  140,489
                                                        ==========










            See notes to consolidated financial statements


                                       3
<PAGE>

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                  For the Three            For the Nine
                                  Months Ended             Months Ended
                                  September 30,             September 30,
                                 2005          2004       2005        2004
                                     (Unaudited)            (Unaudited)

TOTAL ROYALTY REVENUES        $      -     $    -     $      -     $     -
                              ------------ ---------- ------------ ----------

OPERATING EXPENSES:
  General and
    administrative                 47,042     58,595      161,535    153,545
  Research and
    development                     4,111        505        7,342      9,929
                              ------------ ---------- -----------  ---------

  Total operating expenses         51,153     59,100      168,877    163,474
                              ------------ ---------- ------------ ---------


LOSS FROM OPERATIONS              (51,153)   (59,100)    (168,877)  (163,474)
                              -----------  ---------  -----------  ---------

OTHER INCOME (EXPENSE):
  Gain from sale of subsidiary         -      60,000          -       60,000
  other income, net                 2,909      8,597        9,498      8,597
                              -----------  ---------  -----------  ----------

  Total other income, net           2,909     68,597        9,498     68,597
                              -----------  ---------- -----------  ---------

(LOSS) INCOME
  BEFORE MINORITY INTEREST        (48,244)     9,497     (159,379)   (94,877)

MINORITY INTEREST                   6,265    153,137       16,823    166,468
                              ----------- ----------  ----------- ----------

NET (LOSS) INCOME                 (41,979)   162,634     (142,556)    71,591

PREFERRED STOCK DIVIDENDS          (1,891)    (1,891)      (5,674)    (5,674)
                              ----------- ----------  ----------- ----------

NET (LOSS) INCOME APPLICABLE
  TO COMMON STOCKHOLDERS          (43,870)   160,743     (148,230)    65,917

NET (LOSS) INCOME PERCOME SHARE
  (BASIC AND DILUTED)          $      -         .01    $     (.01)   $    -
                              =========== ===========  ===========   =========

Weighed average number
  of common shares
  outstanding                  18,129,493  15,982,993   17,765,226  15,982,993






            See notes to consolidated financial statements.



                                       4
<PAGE>

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CASH FLOWS


                                                     For the Nine
                                                     Months Ended
                                                     September, 30
                                                    2005       2004
                                                  --------   --------
                                                     (Unaudited)
     CASH FLOWS FROM OPERATING ACTIVITIES:

       Net (loss) income                         $(142,556) $ 71,591
       Adjustments to reconcile net
         loss to net cash used in
         operating activities-
           Depreciation and amortization               133        133
           Interest income from amortization
             or discount on notes receivable        (5,439)       -0-
           Minority interest in losses             (16,823)  (166,468)
               Gain on sale of subsidiary              -0-    (60,000)
           Change in assets and liabilities
             Consulting fee payable to
               related party                       (26,000)    18,000
             Accounts payable                      (29,303)    (3,160)
             Accrued interest payable                 (115)     2,606
             Accrued payroll and related taxes     (32,521)       -0-
                                                  --------   --------
                Net cash used in
                  operating activities            (252,624)  (137,298)
                                                  --------   --------

     CASH FLOWS FROM INVESTING ACTIVITIES:
       Proceeds from sale of subsidiary                        30,000
       Proceeds from note receivable               135,000        -0-
                                                  --------   --------
                       Net cash provided by
                         investing activities      135,000     30,000
                                                  --------   --------

     CASH FLOWS FROM FINANCING ACTIVITIES:
       Proceeds from notes payable                  52,000    114,970
       Payments on notes payable                   (37,433)    (6,000)
       Proceeds from sale of common stock          150,650        -0-
                                                  --------   --------
                Net cash provided by
                  financing activities             165,217    108,970
                                                  --------   --------








           See notes to consolidated financial statements.



                                       5
<PAGE>

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

                                                       For the Nine
                                                       Months Ended
                                                       September 30,
                                                     2005       2004
                                                   ---------- -------
                                                       (Unaudited)


   NET INCREASE IN CASH                           47,593        1,672

   CASH AT BEGINNING OF PERIOD                     3,600        1,226
                                                 -------     --------

   CASH AT END OF PERIOD                        $ 51,193      $ 2,898
                                                 =======      =======






































          See notes to consolidated financial statements.


                                       6
<PAGE>

INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)


1.       Basis of Presentation

The  accompanying  unaudited  consolidated  financials  statements  of  InMedica
Development  Corporation  and its  majority  owned  subsidiary,  MicroCor,  Inc.
(collectively  the Company)  have been  prepared on a going  concern basis which
contemplates  the  realization of assets and  satisfaction  of liabilities  that
might be necessary  should the Company be unable to continue as a going concern.
The Company  generated a net loss from  operations  of $168,877 and $164,474 for
the nine month periods  ended  September  30, 2005 and 2004,  respectively,  and
negative cash flows from  operations of $252,624 and $137,298 for the nine month
periods  ended  September 30, 2005 and 2004,  respectively.  As of September 30,
2005,  the Company had an accumulated  deficit of  $8,373,256.  At September 30,
2005, the Company had a stockholder's deficit of $23,791. These conditions raise
substantial  doubt as to the Company's  ability to continue as a going  concern.
The Company's  continued  existence is dependent upon its ability to execute its
operating plan and to obtain additional debt or equity  financing.  There can be
no assurance that the necessary debt or equity  financing will be available,  or
will be available on terms  acceptable  to the Company.  Management's  operating
plan  includes  working with Wescor to complete  research,  development  and, if
warranted,   marketing  of  its  hematocrit  technology  and/or  pursuing  other
strategic alliances and licensing  agreements such as the current Agreement with
Wescor, Inc. See Item 2 - "Management's Discussion and Analysis."

The accompanying consolidated financial statements of the Company are unaudited.
However,  in management's  opinion,  all adjustments,  consisting only of normal
recurring adjustments necessary for fair presentation of results for the interim
periods shown,  have been made.  Results for interim periods are not necessarily
indicative  of  those  to be  expected  for the full  year.  These  consolidated
financial statements should be read in conjunction with the audited consolidated
financial statements and notes to consolidated  financial statements included in
the Company's annual report on form 10-KSB for the year ended December 31, 2004.




                                       7
<PAGE>

2.       Summary of Significant Accounting Policies

Principles of Consolidation - The consolidated  financial statements include the
accounts of InMedica  and  MicroCor.  All  material  inter-company  accounts and
transactions have been eliminated.

Use of Estimates - The  preparation of financial  statements in conformity  with
accounting  principles  generally  accepted  in the  United  States  of  America
requires  management to make estimates and assumptions  that affect the reported
amounts  of assets and  liabilities  and  disclosure  of  contingent  assets and
liabilities at the date of the financial  statements and the reported amounts of
revenues and expenses during the reporting  period.  Actual results could differ
from those estimates.

                    BALANCE OF THIS PAGE INTENTIONALLY BLANK




























                                       8
<PAGE>




Item 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF
        OPERATION

OVERVIEW.  Since 1989, the Company has engaged in research and  development of a
device  to  measure  hematocrit   non-invasively  the  "Non-Invasive  Hematocrit
Technology"  and/or the "Technology") and fund raising to finance the payment of
research,  development and administrative expenses. Hematocrit is the percentage
of red blood cells in a given volume of human blood.  Research,  development and
administrative  expenses of the Company  relating to the Technology  were funded
during  the  1990's by  borrowing  and by  royalty  revenues  from the sale of a
portable ECG monitor  which  incorporated  Company  technology.  The monitor was
marketed by  Critikon,  Inc.,  then a Johnson and  Johnson  subsidiary.  However
Critikon  discontinued  the  monitor  in 2001 and  InMedica  has not  since  had
revenues from Operations. During 2001 the Company and its subsidiary,  MicroCor,
Inc. sold restricted common stock to Chi Lin Technologies,  Ltd. of the Republic
of China  (Taiwan)  for  $1,000,000  and used the funds to  continue  funding of
research,  development  and  administrative  expenses.  Chi Lin  also  signed  a
development agreement under which it performed or financed the Company's primary
research and development  effort conducted  initially in Taiwan and later in the
United States.  When payments from the stock sale were expended during 2003, the
Company  began  searching  for  additional  funding  and/or a partner to conduct
additional  research and development.  The Company's  officers and Chairman also
agreed to the  accrual of their wages and  consulting  fees  pending  receipt of
funds to pay those obligations. In January 2005, the shareholders of the Company
approved  an  Agreement  with  Wescor  which  provides  additional  funding  for
administrative  expenses  and  provides  for  research  and  development  of the
Hematocrit Technology by Wescor.

PLAN OF OPERATION.  During the 12 months beginning  January,  2005 the Company's
plan of operation is to work  cooperatively  with Wescor in the  development and
possible  demonstration  of the Company's  portable  hematocrit  device to other
companies.   In   connection   with  this  effort,   the  Company  will  require
confidentiality  agreements  from parties to which  disclosure  is made and will
allow such parties to informally  evaluate the  technology in order to determine
their  interest.  During  2005,  Wescor is  expected  to fund the  research  and
development  efforts of MicroCor  pursuant to the Joint  Development  Agreement.


                                       9
<PAGE>

During  2004,  the  Company  borrowed  from  Wescor  in order to meet  operating
expenses and may need to rely on  borrowing  in the future to meet  obligations.
While the Company has in the past borrowed from  affiliates,  such  borrowing is
not  expected  to be  available  in the  future  to meet  obligations  and  fund
continued research and development.  If necessary,  InMedica will look for other
funding sources.

LIQUIDITY AND CAPITAL RESOURCES.

The funds  generated  from the sale of stock in 2001 were the sole source of the
Company's  cash  flow  from  May 10,  2001  until  December  31,  2003  and were
sufficient to meet the Company's  operating  expenses only through  December 31,
2003. During the year 2004 liquidity was generated by borrowings from Wescor and
from  the  proceeds  of the  sale of  MicroCor  stock  to  Wescor  and  sales of
restricted  stock to  members of  management.  The  Company  expects to fund its
administrative  operations during 2005 with funds from installment payments from
Wescor for the  purchase  of the  MicroCor  stock and with  additional  sales of
restricted  common  stock to  Company  insiders  and  other  private  investors.
Research and  development  efforts of Wescor will be  compensated  by additional
issuances of MicroCor stock pursuant to the Joint Development Agreement.

During the nine months  ended  September  30, 2005 cash flow was  provided  from
installment  payments from Wescor, Inc., a Utah based medical technology company
that agreed to conduct  additional  research and  development  of the  Company's
hematocrit  technology  pursuant to an  agreement  dated  September 7, 2004 (the
"Agreement").  See Form 8-K filed  September 14, 2004.  Among other things,  the
Agreement may result in the disposition of ownership of part or all of the stock
of  MicroCor,  Inc. the  Company's  subsidiary  that owns all of the  hematocrit
patents, business and intellectual property.  However, payments made to InMedica
from the sale of  MicroCor  stock  are  expected  to  provide  funding  of basic
administrative  expenses of the Company during the next 14 months.  If Wescor is
successful  in  completing  the  development,  regulatory  approvals and product
introduction,  the  Company  would also be entitled to a royalty on sales of the
product.





                                       10
<PAGE>

RESULTS OF OPERATIONS.

InMedica incurred net losses from operations during the nine month periods ended
September  30,  2005  and  2004.  The  Company  had an  accumulated  deficit  of
$8,373,256 as of June 30, 2005. No revenues from  operations are expected in the
foreseeable  future.  The net loss from  operations  for the three month  period
ended  September  30,  2005  decreased  to $51,153  compared  to the net loss of
$59,1008  for 2004  primarily  due to a decrease in general  and  administrative
expenses.

Item 3:   CONTROLS AND PROCEDURES

The  Company's  Chief  Executive   Officer  and  Chief  Financial  Officer  have
concluded,  based  on  an  evaluation  required  by  paragraph  (b)  of  Section
240.13a-15 or 240.15d-15  of the Rules of the  Securities  Exchange Act of 1934,
conducted as of the end of the period covered by this  Quarterly  Report on Form
10-QSB,  that the Company's  disclosure  controls and  procedures (as defined in
Exchange Act Rules 13a - 15e or 240.15d-15(e)) have functioned effectively.  For
purposes  of this  Item,  the term  DISCLOSURE  CONTROLS  AND  PROCEDURES  means
controls  and other  procedures  of the Company that are designed to ensure that
information required to be disclosed by the Company in the reports that it files
or  submits  under  the  Securities  Exchange  Act (15  U.S.C.  78a ET  SEQ.) is
recorded, processed,  summarized and reported, within the time periods specified
in the Commission's rules and forms. Disclosure controls and procedures include,
without limitation,  controls and procedures designed to ensure that information
required to be  disclosed by the Company in the reports that it files or submits
under  the Act is  accumulated  and  communicated  to the  issuer's  management,
including its principal executive and principal  financial officers,  or persons
performing similar functions, as appropriate to allow timely decisions regarding
required disclosure.

There have been no changes in the  Company's  internal  control  over  financial
reporting identified in connection with the evaluation required by paragraph (d)
of Section 240.13a-15 or 240.15d-15 of the Rules of the Securities  Exchange Act
of 1934,  that occurred  during the Company's last fiscal quarter (the Company's
fourth  fiscal  quarter in the case of an annual  report)  that have  materially
affected,  or are reasonably likely to materially affect, the Company's internal
control over financial reporting.






                                       11
<PAGE>

 PART II - OTHER INFORMATION

Item 1.  Legal Proceedings: None

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds: During the
last three years the Company made the  following  sales of  unregistered  common
stock in reliance  upon Section 4(2) of the  Securities  Act of 1933:  5/2/2005,
715,500 shares to Chi Lin Technology  Company,  Ltd.;  1/24/05 440,000 shares to
Larry E. Clark;  1/19/05 101,000 shares to Richard  Bruggeman;  12/30/04 240,000
shares to Ralph Henson; 10/14/04 400,000 shares to Larry E. Clark. The foregoing
sales were of  restricted  securities  and were  issued to  officers,  directors
and/or principal  shareholders of the Company who purchased the securities based
upon their  representations  that they were purchasing for their own account and
not for resale.

Item 3.  Defaults Upon Senior Securities: None

Item 4.  Submission of Matters to a Vote of Security
         Holders: None

Item 5.  Other Information:  Status of the Joint Development  Agreement and Risk
Factors

Wescor,  Inc.  has advised  the Company  that it has,  through  MicroCor,  Inc.,
completed a prototype of the hematocrit device suitable for conducting  clinical
trials  necessary to prepare for a submission to the FDA for regulatory  review.
As a result,  the board of directors of MicroCor,  Inc., the Company's 68% owned
subsidiary,  has voted to issue 500,000 shares of the restricted common stock of
MircroCor to Wescor pursuant to the Joint Development  Agreement dated September
7, 2004.  The  issuance of this stock was  approved on January  24,  2005,  at a
meeting of the  Shareholders  of the  Company.  Following  the  issuance  of the
MicroCor stock,  MicroCor,  Inc. will be a 57% owned  subsidiary of the Company.
Wescor  will  then own 29% and Chi Lin  Technology  Company,  Ltd.  will own the
balance  (14%)  of  MicroCor,Inc.   Further  development  and  progress  on  the
hematocrit device is subject to continued risks, including the following:

     1. Substantial  Operating Losses.  Since InMedica  commenced  operations in
1983, it has incurred substantial operating losses and it has a retained deficit
of $8,373,256 as of September 30, 2005.  There is no assurance  that  profitable
operations will be achieved in the future.



                                       12
<PAGE>

     2. Financing Necessary. To date the Company's cash flow from operations has
not been  sufficient  to provide  required  working  capital and the Company has
relied upon  borrowing and  contractual  arrangements  (including the sale of an
increasing  percentage of rights in the  hematocrit  technology)  to develop the
hematocrit  device.  The  Company's  limited  revenues have been used to finance
operations and research and  development.  The future success of the Company may
depend  entirely  upon the success of  additional  fund raising from third party
sources (as to which there is no commitment).

     3. Competition and Technological  Change. The medical technology markets in
which the Company competes or proposes to compete are extremely  competitive and
characterized by major companies which are dominant in the various markets.  The
Company is not a competitive  factor in those  markets.  Further,  the Company's
proposed product areas are characterized by rapid  technological  change.  There
can be no assurance that research and development of products by others will not
render the Company's products or processes obsolete.

     4. Dependence on Key Personnel.  The Company's  ability to develop products
and successfully compete in the marketing of such products will be substantially
dependent upon the experience,  abilities and services of the present  officers,
employees and directors of the Company and Wescor, Inc. The loss of the services
of one or more of these persons could have an adverse  effect on the business of
the  Company.  There  is no  assurance  that  the  Company  and  Wescor  will be
successful in retaining existing officers, directors and employees or attracting
additional qualified personnel as needs arise.

     5. Contractual Limitations. Wescor has the contractual right to discontinue
the hematocrit project, in its sole discretion, at any time.

     6. Government Regulation.  The Company's products are subject to regulation
by the Food and Drug  Administration  (the "FDA") both with respect to marketing
and the manner in which  products  are  manufactured.  There is no  assurance of
future  success in  meeting  regulatory  requirements  for FDA  approval  of the
hematocrit device.



                                       13
<PAGE>

     7. Possible Additional  Development.  Clinical trials or further evaluation
may result in the need to do  additional  development  work with  respect to the
hematocrit  device.  Such  development  may be expensive and time  consuming and
there is no assurance of success.

     8. No Dividends.  The Company has paid no dividends on its common stock and
does not intend to pay any dividends in the foreseeable future.

     9. Risks  Inherent  in Common  Stock  Ownership.  The  common  stock of the
Company is subject to fluctuations in market price due to market conditions, 144
sales and results of operations; in the event of liquidation of the Company, the
common  shareholders  would have last priority for  distribution  of any assets,
after creditors and preferred shareholders;  the market for the Company's common
stock is thinly  traded and there is no  assurance  that a market for the common
stock  will  exist  at a time  when a  shareholder  wishes  to  liquidate  stock
ownership.


Item 6.   Exhibits:

(20)     Press release dated November 2, 2005

(31.1)   Sarbanes-Oxley Section 302 Certification - Ralph Henson

(31.2)   Sarbanes- Oxley Section 302 Certification- Richard Bruggeman

(32.1)   Sarbanes-Oxley Section 906 Certification

(99)     Photograph of the hematocrit prototype designed by Wescor, Inc.

Reports on Form 8-K: None



                                       14
<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                            INMEDICA DEVELOPMENT CORPORATION


                            /s/ Ralph Henson ___
                                By Ralph Henson, President


                            /s/ Richard Bruggeman
Date:  November 2, 2005      By Richard Bruggeman, Treasurer





























                                       15
<PAGE>





                EXHIBIT INDEX - INMEDICA DEVELOPMENT CORPORATION
                         FORM 10QSB - SEPTEMBER 30, 2005

EXHIBIT NUMBER    DESCRIPTION

      20          Press Release dated November 2, 2005
      31.1        Section 302 Certifications of Ralph Henson
      31.2        Section 302 Certifications of Richard Bruggeman
      32.2        Sarbanes-Oxley Section 906 Certification
      99          Photograph of the hematocrit device
                  designed by Wescor, Inc.



                                       16